Stage III Lymph Node–Positive Non‐Small‐Cell Lung Cancer Patients With or Without Lymph Node Irradiation by Stereotactic Body Radiation Therapy: Propensity Score–Matched Analysis
The Clinical Respiratory Journal · 2026-05 · 20 (5)
DOI: 10.1111/crj.70191 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 08.05.2026. Verfasst von Zhen Jia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Changhai Hospital Affiliated to Navy Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery, Lymph Nodes. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Changhai Hospital, Navy Medical University, Shanghai Health Commission Leading Talent Program, Changhai Hospital of Shanghai.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
This study compared the local control (LC) and survival of patients with stage III lymph node–positive non‐small‐cell lung cancer (NSCLC) who received lymph node irradiation (LNs R+) and those who did not (LNs R−).
Methods
We retrospectively reviewed patients with stage III LN–positive NSCLC who underwent stereotactic body radiotherapy (SBRT) with or without lymph node irradiation between January 2013 and December 2018. Using propensity score matching (PSM) analyses, we compared the rates of LC, progression‐free survival (PFS), overall survival (OS), and acute/late toxicities between the two groups.
Results
We retrospectively analyzed 201 patients, of whom 52 received LN irradiation and 149 did not. The median LC and OS were 59.7 months (95% CI: 51.1–62.9 months) and 36.3 months (95% CI: 32.6–40.0 months), respectively. After the PSM analysis, 52 patients were included in each group. The median LC (30.6 months and not reached, HR 1.296, 95% CI: 0.733–2.294, p = 0.371) and OS (30.3 months and 31.6 months, HR 0.969, 95% CI: 0.628–1.496, p = 0.887) were similar between the LN R+ group and the LN R− group. Total tumor size, tumor location, and biologic equivalent dose (BED) were independently associated with LC ( p < 0.05). The incidences of acute radiation esophagitis ( p = 0.006) and late pulmonary interstitial fibrosis ( p = 0.046) were significantly higher in the LN R+ group than in the LN R− group.
Conclusions
SBRT is safe and effective in stage III LN–positive NSCLC patients. Omitting elective nodal irradiation achieves comparable survival to irradiating involved lymph nodes while significantly reducing toxicity. These findings support the development of novel combination strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Changhai Hospital Affiliated to Navy Medical University, Shanghai, China.
ORCID-Profile: Zhen Jia, Xiaofei Zhu
Förderung
- Changhai Hospital, Navy Medical University
- Shanghai Health Commission Leading Talent Program
- Changhai Hospital of Shanghai
Zitieren
APA
Jia, Z., Fang, F., Zhu, X., Cao, Y., & Zhang, H. (2026). Stage III Lymph Node–Positive Non‐Small‐Cell Lung Cancer Patients With or Without Lymph Node Irradiation by Stereotactic Body Radiation Therapy: Propensity Score–Matched Analysis. The Clinical Respiratory Journal, 20(5). https://doi.org/10.1111/crj.70191
Vancouver
Jia Z, Fang F, Zhu X, Cao Y, Zhang H. Stage III Lymph Node–Positive Non‐Small‐Cell Lung Cancer Patients With or Without Lymph Node Irradiation by Stereotactic Body Radiation Therapy: Propensity Score–Matched Analysis. The Clinical Respiratory Journal. 2026;20(5). doi:10.1111/crj.70191
BibTeX
@article{Jia2026,
author = {Jia, Zhen and Fang, Fang and Zhu, Xiaofei and Cao, Yangsen and Zhang, Huojun},
title = {Stage III Lymph Node–Positive Non‐Small‐Cell Lung Cancer Patients With or Without Lymph Node Irradiation by Stereotactic Body Radiation Therapy: Propensity Score–Matched Analysis},
journal = {The Clinical Respiratory Journal},
year = {2026},
volume = {20},
number = {5},
doi = {10.1111/crj.70191}
}
EUVIMED